Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 6/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086107 | 1.00 | LMNA (0.42) | LMNACYP1A2CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL1178748 | 0.83 | MAPK1 (0.44) | LMNACYP1A2CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL3097555 | 0.80 | MAPK1 (0.47) | LMNACYP1A2CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL1180045 | 0.77 | MAPK1 (0.47) | LMNACYP1A2CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL12410776 | 0.76 | LMNA (0.52) | LMNACYP1A2CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL3094255 | 0.75 | MAPK1 (0.59) | LMNACYP1A2CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL1178746 | 0.74 | LMNA (0.39) | LMNACYP1A2CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL3086529 | 0.72 | GAA (0.39) | LMNAALDH1A1L3MBTL1GAAMAPT | |
| SCHEMBL12410906 | 0.72 | GAA (0.52) | LMNACYP1A2CYP2C19NPSR1ALDH1A1 | |
| SCHEMBL3087925 | 0.71 | RAB9A (0.48) | LMNACYP1A2ALDH1A1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217594-B1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8299086-B2 | Pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-16 | — | — | US | disclosed |
| EP-2217594-A2 | NOVEL PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009057079-A2 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | LMNA 4595/4885CYP1A2 1444/4885CYP2C19 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.